News
12-13-2008, 05:27 AM
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced data from an open-label phase 2 clinical trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These data suggest that neratinib has antitumor activity in patients with advanced breast cancer positive for the ErbB-2 receptor (also known as HER-2 or Neu). These data were presented today during an oral session at the CTRC-AACR San Antonio Breast Cancer Symposium.
More... (http://www.medicalnewstoday.com/articles/132916.php)
More... (http://www.medicalnewstoday.com/articles/132916.php)